T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus
January 11 2021 - 6:19PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens, today announced that its
T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects
SARS-CoV-2, the virus responsible for COVID-19 infections—is
capable of detecting the multiple variants of the SARS-CoV-2 virus
most recently identified in the United Kingdom, South Africa, and
the United States.
“As new strains of the COVID-19 virus emerge, it is critical
that we ensure our technology continues to be an effective
diagnostic solution during the ongoing pandemic,” said T2
Biosystems’ President and CEO, John Sperzel. “I’m proud that we can
confidently say, after extensive analysis, that our T2SARS-CoV-2
Panel, which has demonstrated clinical sensitivity of 95 percent
and specificity of 100 percent, can continue to help impact lives
by detecting multiple variants of the SARS-CoV-2 virus.”
Both the variants identified in the United Kingdom (B.1.1.7) and
South Africa (B.1.351) contain multiple mutations, most reflected
in the S gene, which encodes the spike protein. To confirm that the
T2SARS-CoV-2 Panel would detect these variants and other potential
mutations of SARS-CoV-2 viruses, an in silico analysis was
performed using genome sequences available in the National Center
for Biotechnology Information (NCBI) nucleotide database and GISAID
database.
Over 42,000 genome sequences for SARS-CoV-2 were evaluated for
alignment with primer and probe sequences from T2SARS-CoV-2 Panel.
This analysis demonstrated that the T2SARS-CoV-2 Panel should
detect 99.99% of all SARS-CoV-2 viruses based on sequence
alignments. A specific analysis of sequences for B.1.1.7 and
B.1.351 variants confirmed that the T2SARS-CoV-2 Panel should be
able to detect these variants.
The T2SARS-CoV-2 Panel provides results in under two hours
utilizing an upper respiratory swab sample. The test runs on the
Company’s FDA-cleared and fully-automated T2Dx® Instrument, which
is capable of performing seven tests simultaneously and up to sixty
samples per day.
The same T2Dx Instrument is also capable of running the
FDA-cleared T2Bacteria® Panel and T2Candida® Panel. These panels
are the only FDA-cleared assays for the detection of sepsis-causing
bacterial and fungal pathogens directly from whole blood in three
to five hours, without the need to wait days for blood culture
results. By providing quicker results, the panels enable clinicians
to target therapy faster for their patients suspected of sepsis,
often before the second dose of antimicrobial medicine is
administered, leading to better patient outcomes, improved
antimicrobial stewardship, and reductions in length of stay in the
hospital.
These additional panels remain especially clinically relevant
during the pandemic, as data suggests that the COVID-19 virus can
lead to sepsis, and death.
About T2 BiosystemsT2 Biosystems, a leader
in the rapid detection of sepsis-causing pathogens, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, T2Candida®
Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the
T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the T2Cauris™ Panel, and
T2Lyme™ Panel, as well as additional products for the
detection of bacterial and fungal pathogens and associated
antimicrobial resistance markers, and biothreat pathogens.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including, without limitation, statements regarding the ability of
the T2SARS-CoV-2 Panel to detect multiple variants of the
SARS-CoV-2 virus, as well as statements that include the words
“expect,” “intend,” “plan”, “believe”, “project”, “forecast”,
“estimate,” “may,” “should,” “anticipate,” and similar statements
of a future or forward looking nature. These forward-looking
statements are based on management's current expectations. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, (i) any inability to (a)
realize anticipated benefits from commitments, contracts or
products; (b) successfully execute strategic priorities; (c) bring
products to market; (d) expand product usage or adoption; (e)
obtain customer testimonials; (f) accurately predict growth
assumptions; (g) realize anticipated revenues; (h) incur expected
levels of operating expenses; or (i) increase the number of
high-risk patients at customer facilities; (ii) failure of early
data to predict eventual outcomes; (iii) failure to make or obtain
anticipated FDA filings or clearances within expected time frames
or at all; or (iv) the factors discussed under Item 1A. "Risk
Factors" in the Company's Annual Report on Form 10-K for the year
ended December 31, 2019, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 16, 2020, and other filings
the Company makes with the SEC from time to time. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While
the Company may elect to update such forward-looking statements at
some point in the future, unless required by law, it disclaims any
obligation to do so, even if subsequent events cause its views to
change. Thus, no one should assume that the Company’s silence over
time means that actual events are bearing out as expressed or
implied in such forward-looking statements. These forward-looking
statements should not be relied upon as representing the Company's
views as of any date subsequent to the date of this press
release.
Media Contact:Gina Kent, Vault
Communicationsgkent@vaultcommunications.com 610-455-2763
Investor Contact:Philip Trip Taylor, Gilmartin
Groupphilip@gilmartinIR.com415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Aug 2024 to Sep 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Sep 2023 to Sep 2024